OCT  and thermostatic hyperthermia may be a safe and non-invasive alternative to surgical tumour removal for patients with Superficial basal cell carcinoma. According to the US company, the research mainly focuses on optimizing heat therapy for basal cell carcinoma by laser technology, optical coherence tomography and near-infrared temperature monitoring. The researchers intend to enrol 40 subjects, six of whom have already started treatment with controlled hyperthermia and mapped protocols. a 5mm contour was added by OCT. It is then treated with an ND: YAG laser at 1064 nm while the skin surface temperature is monitored with an infrared camera. 8 to 12 weeks routine check-up to check tumour progression or how much the tumour ablated. 

 Among the patients after 8 weeks of follow-up, the treated area healed well with no scars or complications. 

 While the gathering of preliminary data is there,  more data on squamous BCC and more data on laser therapy should be there for regular use as treatment shortly according to the authors.

A study found that Linfield Confocal Optical Coherence Tomography may help in clinical check-up of Superficial Basal Cell Carcinoma when treated with Imiquimod 5% Cream. A Pilot Study aimed to investigate whether LCOCT might be useful in improving surveillance of superficial basal cell carcinoma in various patients receiving 5% QI Cream, an immune response modulator currently approved in Europe and the United States. In our experience, LCOCT was able to produce asymptomatic signs of CBC after treatment, followed by subsequent cycles of 5% IQ cream. 

 Imiquimod 5% Cream is currently an approved immune response modulator for the treatment of superficial small basal cell carcinoma. 

 This study aimed to determine if LCOCT could be useful in improving the follow-up of BCC treatment. Twenty superficial CBCs from 12 patients were treated with 5% IQ  cream once daily, 5 days a week for 6 weeks. At the end of the Study  13 lesions had a complete clinical response and an LCOCT response, 4 lesions had a familiar partial clinical response and an LCOCT response, while 3 lesions presented with the complete clinical response but residual tumour signs on LCOCT. Our pilot study suggests that LCOCT can be a promising tool to improve the evaluation of the CBC’s therapeutic response to non-invasive treatment. Our pilot study suggests that LCOCT may be a promising tool for improving the assessment of the therapeutic response of CBC to non-invasive treatments such as 5% IQ  cream. 

 In conclusion, our data indicate that LCOCT may show microscopic signs of residual disease which appear to be clinically cured in some superficial CBCs treated with 5% IQ  cream, suggesting further treatment.